A prospective evaluation of ultrasound as a diagnostic tool in acute microcrystalline arthritis.

The performance of ultrasound (US) in the diagnosis of acute gouty (MSU) arthritis and calcium pyrophosphate (CPP) arthritis is not yet well defined. Most studies evaluated US as the basis for diagnosing crystal arthritis in already diagnosed cases of gout and few prospective studies have been performed. One hundred nine consecutive patients who presented an acute arthritis of suspected microcrystalline arthritis were prospectively included. All underwent an US of the symptomatic joints(s) and of knees, ankles and 1(st) metatarsopalangeal (MTP) joints by a rheumatologist "blinded" to the clinical history. 92 also had standard X-rays. Crystal identification was the gold standard. Fifty-one patients had MSU, 28 CPP and 9 had both crystals by microscopic analysis. No crystals were detected in 21. One had septic arthritis. Based on US signs in the symptomatic joint, the sensitivity of US for both gout and CPP was low (60% for both). In gout, the presence of US signs in the symptomatic joint was highly predictive of the diagnosis (PPV = 92%). When US diagnosis was based on an examination of multiple joints, the sensitivity for both gout and CPP rose significantly but the specificity and the PPV decreased. In the absence of US signs in all the joints studied, CPP arthritis was unlikely (NPV = 87%) particularly in patients with no previous crisis (NPV = 94%). X-ray of the symptomatic joints was confirmed to be not useful in diagnosing gout and was equally sensitive or specific as US in CPP arthritis. Arthrocenthesis remains the key investigation for the diagnosis of microcrystalline acute arthritis. Although US can help in the diagnostic process, its diagnostic performance is only moderate. US should not be limited to the symptomatic joint. Examination of multiple joints gives a better diagnostic sensitivity but lower specificity

Les connectivites: progrès thérapeutiques et place de la biothérapie [Connective tissue diseases: news in therapy, role of biologics agents].

Systemic lupus erythematosus and primary Sjögren's syndrom are the two major connective tissue diseases. A better knowledge of their physiopathology allows us today to propose an adapted therapy. Moreover progress concerns the oldest treatment, hydroxychloroquine, and biotherapy. Hydroxychloroquine is still an actual treatment for lupus, its positive effects are better understood today. Nevertheless it does not seem to be efficient to treat primitive Sjögren. Biotherapy targeting B lymphocytes seems efficient in these two connective tissue diseases. Anti TNF therapy is not recommended and seems to induce connective tissue diseases. The real news is the recent approval and reimbursement in Switzerland of the new drug belimumab (Benlysta) in case of moderate lupus

Rhumatologie. Canakinumab: un traitement prometteur [Canakinumab: a promising treatment in rheumatology].

In auto-inflammatory diseases, the role of the inflammasome and the interleukine IL-1beta has recently been shown. Thus, the physiopathology of rare diseases as Cryopyrin-associated periodic syndrome (CAPS) is better understood. In the era of biologics, new treatments targeting IL-1 have been developped. Canakinumab is a fully humanized monoclonal antibody inhibiting specifically IL-1beta Clinical studies have shown its efficacy on clinical symptoms and on inflammatory markers in patients with rare diseases such as CAPS or idiopathic juvenile arthritis, but also in more common rheumatic conditions like gout. Canakinumab has been approved in Switzerland only for the treatment of CAPS. Studies evaluating its effect on cardiovascular diseases are ongoing

Syndrome des anti-synthétases et tacrolimus: efficacité et tolérance, à propos de 2 cas

Introduction. - Le traitement de la polymyosite et de l'atteinte pulmonaireassociées au syndrome des anti-synthétases peut serévéler difficile. Le tacrolimus est proposé en cas d'échec aux autresimmunosuppresseurs. Néanmoins, contrairement aux patientsgreffés, son utilisation dans cette indication est mal codifiée. Nousrapportons les cas de 2 patients traités efficacement par tacrolimus.Cas Clinique. - Cas 1. Il s'agit d'un homme de 44 ans originaire deMadagascar, chez qui le diagnostic de syndrome des anti-synthétasesest posé devant l'association mains de mécanicien, polymyosite,manifestation de raynaud et présence d'anticorps anti Jo1fortement positifs à 281U (norme < 50U). Les différents traitementsproposés (prednisone 1 mg/kg, méthotrexate, azathioprine,rituximab et Immunoglobulines IV) ne permettent pas de contrôlerla situation avec un pic des CK à 24 000 U/l au décours des Ig IV.Une IRM réalisée alors retrouve une activité inflammatoire intensedes compartiments antérieurs et postérieurs des cuisses des 2 côtés.Finalement un traitement de tacrolimus est proposé en augmentationprogressive. L'efficacité du traitement est mesurée par l'évolutiondes CK qui passent en quelques mois de 24 000 U/l à 300 U/lsous une dose de 6 mg/j de tacrolimus et d'une amélioration parIRM spectaculaire. Malheureusement, suite à un épisode de déshydratation,le patient développe une insuffisance rénale aigüemodérée (créatinine à 124 _mol/l contre 89 auparavant) non réversibleaprès réhydratation. Pour stabiliser la fonction rénale le tacrolimusest baissé à 4 mg/jour au prix d'une réapparition des douleursmusculaires et d'une ré-ascension des CK à 1 000 U/l. Cas 2. Il s'agitd'une patiente de 61 ans chez qui le diagnostic de syndrome desanti-synthétases est posé devant l'association atteinte articulaire,mains de mécanicien, atteinte musculaire, pneumopathie interstitiellediffuse et forte positivité des Ac anti JO1 à 252 U. Une associationtacrolimus et prednisone est rapidement proposée en raison del'atteinte pulmonaire. Malheureusement la patiente développe uneinsuffisance rénale progressive sous 9 mg/j de tacrolimus et malgréune réponse favorable sur le plan pulmonaire, le traitement estinterrompu avec amélioration de la fonction rénale.Discussion. - Le tacrolimus est un traitement immunosuppresseuranalogue à la ciclosporine, avec une action 100 fois supérieure. Ilinhibe l'activation et la prolifération des cellules T et sa principaletoxicité est rénale. Traitement puissant, il a montré son efficacitédans les atteintes pulmonaires sévères liées à un syndrome desanti-synthétases1.2. Les pneumologues le connaissent bien et chezles patients greffés, la surveillance de l'efficacité et de la toxicité dutraitement se fait grâce à des mesures du taux résiduel. Néanmoinsdans le cadre du syndrome des anti-synthétases les mesures de surveillancesont moins bien codifiées. Même si l'efficacité du tacrolimussemble excellente dans les formes musculaires etpulmonaires sévères, nos 2 cas nous rendent attentifs sur l'importanced'une surveillance rapprochée de la fonction rénale.Conclusion. - Le tacrolimus est un puissant immunosuppresseur quipeut être proposé aux patients souffrant de manifestations sévèresd'un syndrome des anti-synthétases. Une dose standard n'existe paset il faut être attentif à sa toxicité rénale

Impact of level of expertise versus the statistical tool on vertebral fracture assessment (VFA) readings in cohort studies.

The present study tested if the accuracy of the VFA reading reproducibility is more affected by the statistical tool used or by the reader's level of expertise in 50 VFA from a population-based cohort, the OstéoLaus study. We found that uniform kappa and instruction reading with the ISCD/IOF VFA reading course both increased the accuracy of the reproducibility. Vertebral fractures (VF) due to osteoporosis are under diagnosed. Screening osteoporosis in the general population allows improving management of fragility fracture. It consists to perform a dual X-ray absorptiometry and a spine X-ray to look at a VF. To reduce the dosage of radiation, prevalent or incident VF could be detected by DXA image. The aim of the present study was to test the reproducibility of vertebral fracture assessment (VFA) readings in a population-based cohort and to explore if the accuracy of the reproducibility is more affected by the statistical tool used or by the reader's level of expertise. We calculated the reproducibility of VFA reading by uniform and Cohen's kappa, comparing one expert and one non-expert, before and after an instructional on-line International Society of Clinical Densitometry (ISCD) /International Osteoporosis Foundation (IOF) course on VFA reading. We performed the analysis on 50 VFA from a population-based cohort, the OstéoLaus study. Before the VFA reading course, reproducibility with Cohen's kappa was moderate to poor (0 to 0.520), good with the uniform kappa (0.796 to 0.958). After the course, both Cohen's kappa and uniform kappa statistically increased, ranging from 0.524 to 1.000. For female population-based cohort studies, we recommend using the uniform kappa and instructing a non-expert reader using the ISCD/IOF VFA reading course to correctly read and evaluate the reproducibility of the VFA reading

A pilot study of the efficacy of IL1 blockade by anakinra in acute calcific periarthritis of the rotator cuff

Background/Purpose: Calcific periarthritis of rotator cuff can induce acute and severe shoulder pain and is accompnied by signs of acute inflammation. The calcific deposits are composed of calcium phosphate crystals such as hydroxyapatite or basic calcium phosphate. These crystals stimulate the production and release of IL1b from macrophages, in an analogous manner to MSU and CPPD crystals. As IL1 blockade is effective in reducing signs and symptoms of inflammation in acute gout, we performed a pilot study to study if it is also effective in calcific periarthritis Methods: 5 consecutive patients were included (mean age: 62, 3 females, 2 males) between March 2011 and March 2012. Symptoms of acute shoulder pain at rest had to be present for _7 days before inclusion, associated with limitation of shoulder mobility and the presence on calcification in the rotator cuff by conventional radiography. None of the patients had responded to at least 48 hours of high doses of NSAIDs. Exclusion criteria included no corticosteroid therapy in the last 2 weeks and the exclusion of other rheumatologic or infectious diseases- .Clinical evaluation consisted of patient assessment of pain (total, rest and activity) by VAS (100mm scale) at days 0, 1, 3, 15, 42 and clinical examination of shoulder mobility at days 0, 3, 15. ESR and CRP were measured at days 0, 3. Plain radiographs were performed at days 0 and 15 and an ultrasound examination (including Doppler) was performed at days 0, 3, 15. Anakinra 100mg daily was administered for 3 consecutive days after the first evaluation (day 0). Rescue analgesics were allowed and recorded. Results: At inclusion, all patients had severe shoulder pain: mean (SD) VAS day pain of 72mm (_25mm), mean VAS night pain of 96 (_ 5) and impaired shoulder mobility. CRP was elevated in all of them (mean of 3X). Treatment with anakinra lead to rapid relief of pain in all patients, starting already on the first night following the first injection. The reduction of VAS pain was particularly striking for rest pain: mean (SD) VAS of 4mm (_ 5) at day 1 and this response was maintained for the 5 patients at the end of the three injections without any need of rescue medication. Mean rest VAS was 6 (_8) at day 3. The effect on day pain was less spectacular: mean (SD) VAS at D1 of 30 (_ 18), at D3 of 27 (_ 11). Shoulder mobility also improved and the CRP normalized in 4 of 5 patients at day 3. At day 42, 4 of 5 the patients were still totally asymptomatic. On X rays and US, the calcifications were reduced in size: mean maximal diameter of 21 mm at day 0 to 12 mm at day 15, but did not disappear in any patient. The main change on US was a significant and rapid (at day 3) reduction of Doppler activity around the calcification. Conclusion: This pilot open study suggests that IL-1_ inhibition may be an interesting therapeutic approach in acute calcific periarthritis, especially in patients who have not responded adequately to NSAIDs. The effect on pain seems to be more rapid (within a few hours) than steroid injection although a randomized controlled study needs to be performed to confirm this observation

Ossification du ligament commun cervical postérieur : coexistence de spondylarthrite et d'une hyperostose idiopathique diffuse du squelette

Introduction: L'ossification du ligament commun vertébral postérieur (LCVP) est une hyperostose prédominant au rachis cervical, associée à différentes pathologies constructrices comme l'arthrose, la maladie de Forestier (ou DISH : Diffuse Idiopathic Squeletal Hyperostosis) ou les spondylarthrites (1). Nous rapportons le cas d'une patiente avec ossification cervicale du LCVP, avec coexistence de DISH et de spondylarthrite.Observation: Patiente de 55 ans, d'origine Irakienne, qui présente depuis l'âge de 40 ans des lombalgies et des talalgies attribuées initialement à un métier physique. En 2008, apparait une cervicobrachialgie C6 gauche. L'IRM cervicale retrouve plusieurs hernies discales (C5-C6 et C6-C7 gauches) avec un canal cervical étroit constitutionnel et une ossification du LCVP cervical. Cette ossification est attribuée à un DISH (Figure1). L'échec du traitement conservateur de la névralgie et la menace neurologique de l'ossification du LCVP conduisent en 2010 à une laminectomie C3-C6 avec fixation postérieure (figure 2). En 2011, la patiente consulte en raison de la persistance de cette névralgie, ainsi que pour des lombalgies inflammatoires. La coexistence de ces symptômes inflammatoires et de l'ossification du LCVP nous incite à réaliser une IRM des sacroiliaques qui retrouve une sacroiliite bilatérale (figure 3). Le diagnostic de spondylarthrite HLA B27 négative est retenu devant l'association des signes cliniques et radiologiques. L'étiologie précise quant à l'origine de l'ossification du LCVP reste incertaine, néanmoins un traitement spécifique de la spondylarthopathie est proposé.Discussion: L'ossification du ligament vertébral commun postérieur est une hyperostose dont les principales causes sont le DISH et les spondylarthrites. On retrouve une ossification du ligament commun vertébral, qu'il soit lombaire, cervical ou dorsal, dans 10 à 50 % des DISH, et 3.5 à 30% des spondylarthrites. 4 types d'ossification du LCVP sont décrites : continue, segmentaire, mixte ou circonscrite. Selon Resnick, le DISH se différencie de la spondylarthrite par la présence d'ossifications antérolatérales d'au moins 4 vertèbres contigües sans érosion des sacroiliaques. Cependant on retrouve dans la littérature quelques cas décrivant la coexistence des 2 pathologies. Récemment, Kim et al. Ont rapporté un cas similaire à notre patiente, avec ossification du LCVP cervical et coexistence de DISH et de spondylarthrite (2).Conclusion: Devant la présence d'une ossification du ligament vertébral commun postérieur cervical, il convient de rechercher des signes de DISH et de spondylarthrite, car leur coexistence est possible. La prévalence exacte de cette association reste encore à déterminer

Performance of the assessment in spondyloarthritis international society classification for axial and peripheral spondyloarthritis in an established clinical cohort: Comparison with criteria sets of amor and the european spondylarthropathy study group

10.3899/jrheum.111088Journal of Rheumatology394816-821JRHU

AA amyloidosis treated with tocilizumab: case series and updated literature review.

BACKGROUND: In published case reports, tocilizumab (TCZ) has shown good efficacy for AA amyloidosis in almost all patients. We investigated the efficacy and safety of TCZ in AA amyloidosis in a multicentre study of unselected cases. METHODS: We e-mailed rheumatology and internal medicine departments in France, Switzerland and North Africa by using the Club Rhumatismes Inflammation (CRI) network and the French TCZ registry, Registry RoAcTEmra (REGATE), to gather data on consecutive patients with histologically proven AA amyloidosis who had received at least one TCZ infusion. Efficacy was defined as a sustained decrease in proteinuria level and/or stable or improved glomerular filtration rate (GFR) and by TCZ maintenance. RESULTS: We collected 12 cases of AA amyloidosis treated with TCZ as monotherapy (mean age of patients 63 ± 16.2 years, amyloidosis duration 20.6 ± 31.3 months): eight patients had rheumatoid arthritis (RA), six with previous failure of anti-tumor necrosis factor α (anti-TNF-α) therapy. In total, 11 patients had renal involvement, with two already on hemodialysis (not included in the renal efficacy assessment). For the nine other patients, baseline GFR and proteinuria level were 53.6 ± 32.8 mL/min and 5 ± 3.3 g/24 h, respectively. The mean follow-up was 13.1 ± 11 months. TCZ was effective for six of the eight RA patients (87.5%) according to European League Against Rheumatism response criteria (four good and two moderate responders). As expected, C-reactive protein (CRP) level decreased with treatment for 11 patients. Renal amyloidosis (n = 9) progressed in three patients and was stabilized in three. Overall, three patients showed improvement, with sustained decrease in proteinuria level (42%, 82% and 96%). Baseline CRP level was higher in subsequent responders to TCZ than other patients (p = 0.02). Among the six RA patients with previous anti-TNF-α therapy, amyloidosis was ameliorated in one and stabilized in three. Three serious adverse events occurred (two diverticulitis and one major calciphylaxia due to renal failure). Finally, 7 of 12 (58%) patients continued TCZ. CONCLUSIONS: The efficacy of TCZ for AA amyloidosis varies depending on the inflammatory status at treatment onset. Discrepancies between our study of unselected consecutive patients and reported cases may be due to publication bias. These results support further prospective trials of TCZ for AA amyloidosis